John Verbeten Appointed Compliance Office Director by FDA-CTP in 2024

News by 2FIRSTS.ai
May.14.2024
John Verbeten Appointed Compliance Office Director by FDA-CTP in 2024
John Verbeten appointed as next Office of Compliance Director at FDA-CTP, joining on June 16, 2024, per FDA announcement.

According to the official website of the Food and Drug Administration (FDA) on May 13, the Center for Tobacco Products (CTP) of the FDA announced John Verbeten as the next Director of the Office of Compliance and Regulatory Affairs, and he will officially join on June 16, 2024. Before joining the CTP, Verbeten served as the Deputy Director of Import Operations in the Office of Regulatory Affairs (ORA) at the FDA.

 

Previously, Walberton and the United States Postal Service (USPS) established a memorandum of understanding (MOU) to provide a foundation for tracking data between both parties and grant the FDA the authority to obtain advanced electronic data on USPS import mail.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

COP11 to Convene in Geneva in November; South Korea May Leverage Global Consensus to Advance Tobacco-Control Reforms
COP11 to Convene in Geneva in November; South Korea May Leverage Global Consensus to Advance Tobacco-Control Reforms
The 11th Conference of the Parties (COP11) to the WHO Framework Convention on Tobacco Control (FCTC) will be held in Geneva, Switzerland, from November 7 to 22, 2025. The meeting is expected to focus on the disclosure of tobacco constituents, environmental impacts, and industry responsibility. South Korea plans to implement the Tobacco Harmfulness Management Act in November and is preparing to send a delegation to COP11 to help align domestic regulations with international standards.
Sep.05 by 2FIRSTS.ai
Special Report | EU Cardiovascular Health Plan Consultation Sparks Debate on Regulation of Novel Tobacco Products, Potentially Shaping TPD III
Special Report | EU Cardiovascular Health Plan Consultation Sparks Debate on Regulation of Novel Tobacco Products, Potentially Shaping TPD III
The EU’s consultation on the Cardiovascular Health Plan, though not mentioning nicotine, has sparked debate over novel tobacco regulation. Advocates urge evidence-based recognition of harm reduction products, while opponents call for tighter rules. The plan may influence TPD III, drawing close scrutiny from both industry and health groups.
Sep.01
Greentank Technologies Appoints Chris Gemmell as Chief Product and Innovation Officer
Greentank Technologies Appoints Chris Gemmell as Chief Product and Innovation Officer
Greentank Technologies appoints Chris Gemmell as Chief Product & Innovation Officer, bringing extensive experience from tobacco industry.
Sep.04 by 2FIRSTS.ai
JUUL Labs Accuses NJOY and Altria of Patent Infringement; U.S. ITC Launches Section 337 Investigation
JUUL Labs Accuses NJOY and Altria of Patent Infringement; U.S. ITC Launches Section 337 Investigation
The U.S. International Trade Commission (USITC) has instituted an investigation titled Certain Vaporizer Devices, Cartridges Used Therewith, and Components Thereof (II) based on a complaint by JUUL Labs, Inc. JUUL alleges that NJOY, its parent and affiliates at Altria Group, infringed U.S. Patent No. 12,156,533 through the importation and sale of certain ENDS devices, cartridges, and components. JUUL seeks a limited exclusion order and cease-and-desist orders. Respondents must answer within 20 d
Sep.11 by 2FIRSTS.ai
BAT Korea: Neo Heated Tobacco Stick Series Updated with StickSeal Technology and New Packaging
BAT Korea: Neo Heated Tobacco Stick Series Updated with StickSeal Technology and New Packaging
BAT Korea has fully upgraded its glo hyper-exclusive Neo stick series, applying StickSeal technology across all 10 product variants. The renewal also features the updated “Tobacco Switch” with a cooling capsule and a redesigned packaging concept under “Live Life in Color,” enhancing both user experience and brand identity.
Sep.02 by 2FIRSTS.ai
Experts to Debate Regional THR at first Asia Forum on Nicotine
Experts to Debate Regional THR at first Asia Forum on Nicotine
The first Asia Forum on Nicotine will be held on August 27, 2025, focusing on tobacco harm reduction in Asia. Experts will discuss regulation, scientific evidence, and clinical practice to promote cross-border dialogue and cooperation.
Aug.12